INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Gregory S. Rush as the Company's Executive Vice President and Chief Financial Officer (CFO). Mr. Rush, who will succeed David Gill, has more than 20 years of public accounting and global finance experience in both the public and private company environments. Mr. Rush joins INC Research from Tekelec, a leading high-tech services provider, where he has served as Senior Vice President and CFO since March 2010. Mr. Rush played a key role in the strategic sale of Tekelec to Oracle, which was completed in June 2013.
"Greg Rush brings significant finance expertise to INC Research along with a proven ability to execute on growth plans to drive profitability and performance," said CEO Jamie Macdonald. "His strong technical background rooted in public accounting, experience in both the private equity and public company environments, and repeated success in high-tech companies with a strong service component will serve us well as we continue to execute against our strategy to deliver best-in-class clinical development services and enhanced value for our customers and shareholders."
Mr. Rush joined Tekelec in May 2005 and prior to serving as Senior Vice President and CFO was Chief Accounting Officer of the company. His previous experience includes roles as Senior Director of Finance, External Reporting and Acquisitions for Siebel Systems, Inc., as well as Senior Director, Business Analysis and Financial Reporting for Quintiles Transnational Corp. Mr. Rush's career began with 10 years in public accounting, serving numerous high technology companies at Ernst & Young and PricewaterhouseCoopers. He also played a key role in initial public offerings for Quintiles and Pharmaceutical Product Development, LLC. Mr. Rush received his Bachelor of Science in Business and Master of Accounting degrees from the University of North Carolina at Chapel Hill, graduating with honors, and is a Certified Public Accountant (CPA).
Commenting on his appointment, Mr. Rush said, "INC Research is well positioned for future expansion as a top-tier CRO. I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success through continued strong financial leadership and a balanced profitable growth strategy to create shareholder value."
As CFO for INC Research, Mr. Rush will oversee all of the Company's financial operations, including Finance, Accounting, Tax, Treasury, Budgeting, Mergers and Acquisitions and Financial Planning, as well as its Information Technology function. He will be based at the Company's headquarters in Raleigh, N.C., and will report directly to CEO Jamie Macdonald.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com
"Greg Rush brings significant finance expertise to INC Research along with a proven ability to execute on growth plans to drive profitability and performance," said CEO Jamie Macdonald. "His strong technical background rooted in public accounting, experience in both the private equity and public company environments, and repeated success in high-tech companies with a strong service component will serve us well as we continue to execute against our strategy to deliver best-in-class clinical development services and enhanced value for our customers and shareholders."
Mr. Rush joined Tekelec in May 2005 and prior to serving as Senior Vice President and CFO was Chief Accounting Officer of the company. His previous experience includes roles as Senior Director of Finance, External Reporting and Acquisitions for Siebel Systems, Inc., as well as Senior Director, Business Analysis and Financial Reporting for Quintiles Transnational Corp. Mr. Rush's career began with 10 years in public accounting, serving numerous high technology companies at Ernst & Young and PricewaterhouseCoopers. He also played a key role in initial public offerings for Quintiles and Pharmaceutical Product Development, LLC. Mr. Rush received his Bachelor of Science in Business and Master of Accounting degrees from the University of North Carolina at Chapel Hill, graduating with honors, and is a Certified Public Accountant (CPA).
Commenting on his appointment, Mr. Rush said, "INC Research is well positioned for future expansion as a top-tier CRO. I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success through continued strong financial leadership and a balanced profitable growth strategy to create shareholder value."
As CFO for INC Research, Mr. Rush will oversee all of the Company's financial operations, including Finance, Accounting, Tax, Treasury, Budgeting, Mergers and Acquisitions and Financial Planning, as well as its Information Technology function. He will be based at the Company's headquarters in Raleigh, N.C., and will report directly to CEO Jamie Macdonald.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com